New Triple-Drug attack on advanced kidney cancer being tested
NCT ID NCT06708949
Summary
This study is testing whether adding a third immunotherapy drug to a standard two-drug combination works better for advanced kidney cancer. The trial will compare a three-drug combination against the standard two-drug treatment in patients who haven't received any prior cancer therapy. Researchers want to see if the triple combination is safe and more effective at shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA, CLEAR CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact Email: •••••@•••••
Contact
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.